USFDAJul 1, 2026, 09:32 AM
NewcelX: Successful FDA Pre-IND Meeting for NCEL-101 in Type 1 Diabetes
AI Summary
NewcelX Ltd. announced the successful completion of its Type B Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for NCEL-101. The FDA provided constructive feedback and alignment on the company's proposed development strategy, offering a clear regulatory path toward initiating clinical trials for type 1 diabetes. This milestone supports NewcelX's plan to combine NCEL-101 with Eledon Pharmaceuticals' tegoprubart, an investigational immunomodulatory agent, aiming for a potential functional cure for type 1 diabetes. The FDA's favorable feedback on CMC processes and preclinical programs allows NewcelX to proceed with IND-enabling activities.
Key Highlights
- NewcelX completed a successful Type B Pre-IND meeting with the FDA for NCEL-101.
- FDA provided constructive feedback and alignment on the development strategy for NCEL-101.
- The meeting clarifies the regulatory pathway for clinical trials of NCEL-101 for type 1 diabetes.
- NCEL-101 will be developed in combination with Eledon Pharmaceuticals' tegoprubart.
- FDA gave favorable feedback on NewcelX’s Chemistry, Manufacturing, and Controls (CMC) processes.
- Preclinical data for NCEL-101 shows ~60% Beta cells co-express insulin and NKX6.1.
- NCEL-101 preclinical data indicates 99.98% endocrine lineage.
- More than 96% of NCEL-101 cells are non-proliferative, similar to donor human islets.
Price Impact
More from NCEL